A Phase 4 interventional study of Buprenorphine + naloxone (Suboxone) and Buprenorphine + naloxone (Suboxone) in Opiate Dependence, sponsored by Indivior Inc.. Completed at 8 sites in Taiwan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2012-11-30.
Sponsored by Indivior Inc. · Phase 4, Interventional, and Treatment
To determine whether Suboxone can be effectively used to treat Taiwanese ethnic subjects with opiate dependence.
1,411 studies on the registry are indexed under Opioid-Related Disorders; 290 are open to participants now.
This study's enrollment of 127 is above the median of 63 across 1,123 interventional studies indexed under Opioid-Related Disorders.
Browse Opioid-Related Disorders studies →Indivior Inc. is the lead sponsor of 51 studies on the registry; none are open to participants now.
Of its 14 completed or terminated interventional studies of FDA-regulated products, 11 (79%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Drug: Buprenorphine + naloxone (Suboxone)
Drug: Buprenorphine + naloxone (Suboxone)
Drug: Buprenorphine + naloxone (Suboxone)
Sublingual tablets
Also known as: Suboxone
Also known as: Suboxone
Retention in treatment
Time frame: weekly up to 13 weeks
This study is completed, as verified in Jan 2010. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Indivior Inc.